Efficacy and Safety of Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic Review and Network Meta-Analysis

Table 1

Pooled estimates of the network meta-analysis of ischemic and hemorrhagic endpoints.

Major bleeding
DAPT 12Mo	0.67 (0.26, 1.23)	0.67 (0.31, 1.31)	0.58 (0.32, 1.07)	0.77 (0.46, 1.23)	1.50 (0.95, 2.54)
1.49 (0.81, 3.92)	DAPT 1Mo + P2Y12	1.01 (0.39, 3.15)	0.86 (0.37, 2.81)	1.14 (0.52, 3.39)	2.22 (1.07, 7.12)
1.49 (0.76, 3.27)	0.99 (0.32, 2.59)	DAPT 3Mo + ASA	0.85 (0.36, 2.37)	1.15 (0.50, 2.86)	2.26 (1.02, 5.82)
1.74 (0.94, 3.11)	1.16 (0.36, 2.68)	1.18 (0.42, 2.77)	DAPT 3Mo + P2Y12	1.33 (0.60, 2.75)	2.62 (1.21, 5.63)
1.31 (0.81, 2.17)	0.87 (0.29, 1.91)	0.87 (0.35, 2.01)	0.75 (0.36, 1.67)	DAPT 6Mo	1.98 (1.21, 3.50)
0.67 (0.39, 1.05)	0.45 (0.14, 0.93)	0.44 (0.17, 0.98)	0.38 (0.18, 0.82)	0.50 (0.29, 0.83)	L-DAPT
Any bleeding
DAPT 12Mo	0.74 (0.38, 1.18)	0.74 (0.43, 1.22)	0.58 (0.38, 0.88)	0.76 (0.52, 1.04)	1.48 (1.02, 2.03)
1.35 (0.85, 2.65)	DAPT 1Mo + P2Y12	1.00 (0.51, 2.29)	0.77 (0.43, 1.77)	1.02 (0.58, 2.11)	1.99 (1.13, 4.14)
1.35 (0.82, 2.30)	1.00 (0.44, 1.95)	DAPT 3Mo + ASA	0.79 (0.41, 1.54)	1.03 (0.56, 1.88)	2.01 (1.07, 3.67)
1.73 (1.14, 2.63)	1.29 (0.57, 2.32)	1.27 (0.65, 2.44)	DAPT 3Mo + P2Y12	1.31 (0.75, 2.20)	2.56 (1.46, 4.29)
1.32 (0.96, 1.91)	0.98 (0.47, 1.71)	0.97 (0.53, 1.80)	0.76 (0.45, 1.34)	DAPT 6Mo	1.95 (1.37, 2.74)
0.68 (0.49, 0.98)	0.50 (0.24, 0.89)	0.50 (0.27, 0.94)	0.39 (0.23, 0.68)	0.51 (0.37, 0.73)	L-DAPT
Definite or probable stent thrombosis
DAPT 12Mo	1.20 (0.54, 3.65)	1.25 (0.54, 2.95)	1.00 (0.44, 2.46)	1.09 (0.62, 2.08)	0.58 (0.34, 1.11)
0.83 (0.27, 1.85)	DAPT 1Mo + P2Y12	1.03 (0.25, 3.28)	0.82 (0.21, 2.75)	0.89 (0.28, 2.53)	0.47 (0.15, 1.35)
0.80 (0.34, 1.87)	0.97 (0.30, 3.96)	DAPT 3Mo + ASA	0.79 (0.25, 2.80)	0.87 (0.32, 2.55)	0.46 (0.18, 1.38)
1.00 (0.41, 2.29)	1.23 (0.36, 4.73)	1.26 (0.36, 4.05)	DAPT 3Mo + P2Y12	1.10 (0.39, 3.10)	0.58 (0.21, 1.67)
0.92 (0.48, 1.62)	1.12 (0.39, 3.58)	1.15 (0.39, 3.13)	0.91 (0.32, 2.58)	DAPT 6Mo	0.53 (0.29, 0.98)
1.73 (0.90, 2.91)	2.11 (0.74, 6.59)	2.16 (0.72, 5.66)	1.72 (0.60, 4.73)	1.88 (1.02, 3.40)	L-DAPT
Myocardial infarction
DAPT 12Mo	1.03 (0.66, 1.70)	1.10 (0.69, 1.75)	0.84 (0.52, 1.27)	1.12 (0.82, 1.57)	0.68 (0.51, 0.95)
0.97 (0.59, 1.51)	DAPT 1Mo + P2Y12	1.07 (0.53, 2.04)	0.82 (0.40, 1.45)	1.08 (0.63, 1.92)	0.66 (0.38, 1.17)
0.91 (0.57, 1.46)	0.93 (0.49, 1.90)	DAPT 3Mo + ASA	0.76 (0.39, 1.41)	1.01 (0.59, 1.84)	0.62 (0.36, 1.12)
1.19 (0.79, 1.93)	1.22 (0.69, 2.51)	1.32 (0.71, 2.56)	DAPT 3Mo + P2Y12	1.33 (0.80, 2.45)	0.81 (0.50, 1.51)
0.89 (0.64, 1.22)	0.93 (0.52, 1.60)	0.99 (0.54, 1.71)	0.75 (0.41, 1.25)	DAPT 6Mo	0.61 (0.43, 0.87)
1.47 (1.06, 1.95)	1.52 (0.86, 2.62)	1.62 (0.89, 2.78)	1.24 (0.66, 2.02)	1.63 (1.15, 2.34)	L-DAPT

Results in the upper triangle are odds ratios with 95% confidence intervals from the network meta-analysis between the column defining intervention and row defining intervention. Significant results are in bold. L-DAPT refers to longer-term (>12 months) DAPT, DAPT 12Mo refers to 12-month DAPT, DAPT 6Mo refers to 6-month DAPT, DAPT 3Mo + ASA refers to 3-month DAPT followed by aspirin monotherapy, DAPT 3Mo + P2Y12 refers to 3-month DAPT followed by a P2Y12 receptor inhibitor monotherapy, and DAPT 1Mo + P2Y12 refers to 1-month DAPT followed by a P2Y12 receptor inhibitor monotherapy. DAPT indicates dual antiplatelet therapy.